Treatment of special populations with chronic hepatitis B infection

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 3, 2011, Pages 323-339

  Rapti, Irene N ^a   Hadziyannis, Stephanos J ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

coinfections; decompensated cirrhosis; immunocompromised; pregnant; renal dialysis patients; special populations; treatment of chronic hepatitis B

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; CANCER CHEMOTHERAPY; CANCER RISK; CHILDHOOD DISEASE; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PREGNANT WOMAN; RECURRENT INFECTION; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; MALE; ORGAN TRANSPLANTATION; PATIENT SELECTION; PREGNANCY; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958266564     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.7     Document Type: Review

References (110)

1. Peters M. Special populations with hepatitis B infection. Hepatology 49, S146-S155 (2009).
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
3. Buster EH. Hansen BE, Buti M, et al. Peginterferon a-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46, 388-394 (2007). (Pubitemid 47344773)
4. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudineresistant HBeAg-negative chronic hepatitis B. Hepatology 45, 307-313 (2007). (Pubitemid 46374587)
5. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44, 703-712 (2006). (Pubitemid 44433727)
6. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43, 937-943 (2005). (Pubitemid 41627977)
7. Lai CL, Gane E, Liaw YF et al for the Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007). (Pubitemid 350294224)
8. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of HBV infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 28, 1067-1077 (2008).
9. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t)ide therapy: a systematic review. J. Hepatol. 53, 348-356 (2010).
10. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J. Hepatol. 21, 656-666 (1994). (Pubitemid 24324044)
11. Liaw YF, Lin DY, Chen TJ, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 9, 235-241 (1989).
12. Perrillo RP, Wright T, Rakela J, et al. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-432 (2001). (Pubitemid 32119032)
13. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 13, 349-360 (2007). (Pubitemid 46444463)
14. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34, 411-416 (2001). (Pubitemid 32702355)
15. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50, 2001-2006 (2009).
16. Shim YH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 52, 176-182 (2010).
17. Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int. 28, 814-820 (2008). (Pubitemid 351818643)
18. Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J. Hepatol. 52, 147-149 (2010).
19. Liaw YF, Sheen I-S, Lee C-M, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53(1), 62-72 (2011).
20. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123, 719-727 (2002). (Pubitemid 34977078)
21. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transpl. 14, S1-S7 (2008).
22. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of patients with identification of risk factors. J. Med. Virol. 62, 299-307 (2000).
23. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605-611 (2009).
24. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37, 1320-1328 (2003). (Pubitemid 36667311)
25. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohns disease patients: need for primary prophylaxis. Gut 53, 1363-1365 (2004). (Pubitemid 39120128)
26. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 90, 1306-1311 (2004). (Pubitemid 38586252)
27. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis. 39, 397-408 (2007). (Pubitemid 46508732)
28. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with heamatological malignancies. Br. J. Heamatol. 136, 699-712 (2007).
29. Wursthorn K, Wedemeyer H, Manns M. Managing HBV in patients with impaired immunity. Gut 59, 1430-1445 (2010).
30. Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J. Clin. Virol. 41, 243-254 (2008).
31. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43, 209-220 (2006).
32. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519-528 (2008). (Pubitemid 351665421)
33. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkins lymphoma: a randomized trial. Hepatology 47, 844-853 (2008). (Pubitemid 351449676)
34. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with heamatological malignancy on completion of cytotoxic chemotherapy. Gut 54, 1597-1603 (2005). (Pubitemid 41531779)
35. Lok A. and McMahon B. Chronic hepatitis B: update 2009. AASLD practice guidelines. Hepatology 50, 1-36 (2009).
36. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 10, 968-974 (2004). (Pubitemid 39232749)
37. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting; a European and an American prospective. Liver Transpl. 11, 716-732 (2005). (Pubitemid 40975571)
38. Dickson RC, Terrault NA, Ishitani M, et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl. 12, 124-133 (2006).
39. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132, 931-937 (2007). (Pubitemid 46440868)
40. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 11, 402-409 (2005). (Pubitemid 40533208)
41. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 12, 253-258 (2006). (Pubitemid 43273784)
42. Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48, 1460-1466 (2008).
43. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J. Viral Hepat. 14(Suppl. 1), 37-44 (2007). (Pubitemid 47624113)
44. Gaeta GB, Stornaiuolo G, Precone DF et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J. Hepatol. 39, 1036-1041 (2003). (Pubitemid 37523777)
45. Chu CJ, Lee SD. Hepatitis B virus/ hepatitis C virus co-infection: epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 23, 512-520 (2008).
46. Raimondo G, Brunetto MR, Pontisso P et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus co-infected patients. Hepatology 43, 100-107 (2006). (Pubitemid 43733596)
47. Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-a and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J. Gastroenterol. Hepatol. 20, 727-732 (2005).
48. Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 37, 568-576 (2003).
49. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon a-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136, 496-504 (2009).
50. Liu CJ, Chen PJ, Chen DS. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 40, 266 (2004).
51. Degertekin H, Yalin K, Yakut M. The prevalence of hepatitis d virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk. J. Gastroenterol. 17, 25-34 (2006). (Pubitemid 46534949)
52. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 45, 1331-1332 (2007). (Pubitemid 46775802)
53. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126, 1024-1029 (2004).
54. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon-a-2a. N. Engl. J. Med. 330, 88-94 (1994).
55. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126, 1740-1749 (2004). (Pubitemid 38736339)
56. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis d with pegylated interferon-a 2b. Liver Int. 26, 805-810 (2006). (Pubitemid 44172032)
57. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon a 2-b as monotherapy or in combination with ribavirin in chronic hepatitis d. Hepatology 44, 713-720 (2006). (Pubitemid 44433728)
58. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic d hepatitis with lamivudine vs lamivudine+ interferon vs interferon. J. Viral Hepat. 15, 314-321 (2008). (Pubitemid 351326903)
59. Yurdaydin C, Wedemeyer H, Dalekos G et al. A multicenter randomized study comparing the efficacy of pegylated interferon a-2a plus adefovir dipivoxil vs. pegylated interferon a-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis: the intervention trial (HID-IT). Hepatology 41 (Suppl. 1), A230 (2006).
60. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 44, 536-539 (2006). (Pubitemid 44433709)
61. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44 (Suppl. 1), S6-S9 (2006). (Pubitemid 43053865)
62. Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J. Hepatol. 44, S65-S70 (2006). (Pubitemid 43053877)
63. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19, 221-240 (2005). (Pubitemid 40396554)
64. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B carrier state. J. Infect. Dis. 163, 1138-1140 (1991).
65. Wang HS, Han S-H B. Management of hepatitis B in special patient populations. Clin. Liver Dis. 14, 505-520 (2010).
66. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol. 42, 615-624 (2005).
67. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43, 548-555 (2006).
68. Sheldon JA, Corral A, Rodés B, et al. Risk of selecting K65R in antiretroviralnaive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 19, 2036-2038 (2005). (Pubitemid 41669031)
69. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614-2621 (2007). (Pubitemid 46961006)
70. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22, 947-955 (2008). (Pubitemid 351652245)
71. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIVinfected adults. HIV Med. 9, 82-88 (2008). (Pubitemid 351228130)
72. Hammer SM, Eron Jr JJ, Reiss P for the International AIDS Society USA Panel. Antiretroviral treatment of adult HIV infection. JAMA 300, 555-570 (2008).
73. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49, S138-S145 (2009).
74. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18, (2000).
75. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45, 1056-1075 (2007). (Pubitemid 46646501)
76. Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis-B associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 80, 235-240 (2009).
77. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J. Viral Hepat. 13(4), 256-263 (2006).
78. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J. Viral Hepat. 11, 427-431 (2004). (Pubitemid 39336223)
79. Tassopoulos NC, Koutelou MG, Polychronaki H, et al. Recombinant interferon-a therapy for acute hepatitis B: a randomized, double-blind, placebocontrolled trial. J. Viral Hepat. 4, 387-394 (1997). (Pubitemid 127733500)
80. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J. Hepatol 43, 771-775 (2005). (Pubitemid 41414501)
81. Terrault NA and Jacobson IM. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin. Liver Dis. 27(Suppl. 1), S18-S24 (2007).
82. ter Borg MJ, Leemans WF, de Man RA et al. Exacerbation of chronic hepatitis B infection after delivery. J. Viral Hepat. 15, 37-41 (2008). (Pubitemid 350243581)
83. Nguyen G, Garcia RT, Nguyen N, et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment. Pharmacol. Ther. 29, 755-764 (2009).
84. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J. Gastroenterol. Hepatol. 15(Suppl.), E11-E15 (2000). (Pubitemid 30435729)
85. Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332, 328-336 (2006).
86. Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev. Anti Infect. Ther. 2(1), 133-145 (2004). (Pubitemid 38735754)
87. Xiao XM, Li AZ, Chen X, et al. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int. J. Gynaecol. Obstet. 96, 167-170 (2007). (Pubitemid 46281912)
88. Xu Q, Xiao L, Lu XB, et al. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J. Gastroenterol. 12, 3434-3437 (2006). (Pubitemid 43933793)
89. Wang Z, Zhang J, Yang H, et al. Quantitative analysis of HBV DNA level and HBeAg titre in hepatitis B surface antigen positive mother and their babies: HBeAg passage through the placenta and the rate of decay in babies. J. Med. Virol. 71, 360-366 (2003). (Pubitemid 37176624)
90. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral Hepat. 10, 294-297 (2003). (Pubitemid 36801916)
91. Xu WM, Cui YT, Wang L, et al. Lamivudine in the late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebocontrolled study. J. Viral Hepat 16, 94-103 (2008).
92. Li XM, Yang YB, Hou HY, et al. Interruption of HBV intrauterine transmission: a clinical study. World J. Gastroenterol. 9, 1501-1503 (2003).
93. Han G, Zhao W, Cao M, et al. A prospective and open-label study for the efficacy and safety of telbivudine (LdT) in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 212, Boston, MA, USA, 30 October - 2 November 2010.
94. Reddy PA, Gupta I, Ganguly NK. Hepatitis-B vaccination in pregnancy: safety and immunogenic response in mothers and antibody transfer to neonates. Asia Oceania J. Obstet. Gynaecol. 20, 361-365 (1994).
95. Yang J, Zeng XM, Men YL, et al. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus - a systematic review. Virol. J. 5, 100 (2008).
96. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin. Med. J. 115, 1510-1512 (2002). (Pubitemid 35282912)
97. Hill JB, Sheffield JS, Kim MJ, et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet. Gynecol. 99, 1049-1052 (2002). (Pubitemid 34621230)
98. Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36, 41-66 (1999). (Pubitemid 29056000)
99. Zou H, Chen Y, Duan Z, et al. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 235, Boston, MA, USA, October - 2 November 2010.
100. Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin. Infect. Dis. 45, 943-949 (2007). (Pubitemid 47580340)
101. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon a therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114, 988-995 (1998). (Pubitemid 28217565)
102. Jonas MM, Little NR, Gardner SD; International Paediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: a durability of therapeutic responses and safety. J. Viral Hepat. 15, 20-27 (2008). (Pubitemid 350243578)
103. Jonas MM, Kelly D, Pollack H et al. Safety, efficacy and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to<18 years) with chronic hepatitis B. Hepatology 47, 18631871 (2008). (Pubitemid 351945554)
104. Jonas MM, Block JM, Haber BA et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 52, 21922205 (2010).
105. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in patients on haemodialysis and peritoneal dialysis. Vaccine 23, 3957-3960 (2005).
106. Lapinski TW, Flisiak R, Jaroszewicz J, et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol. 11, 400-402 (2005). (Pubitemid 40125249)
107. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, haemodialysis patients and patients with renal insufficiency. Transplantation 80, 1086-1092 (2005). (Pubitemid 41611932)
108. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 86, 611-614 (2008).
109. Fabrizi F, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis B virus-associated glomerulonephritis. Aliment. Pharmacol. Ther. 24, 781-788 (2006).
110. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome and impact of treatment in patients Medicine (Baltimore) 84, 313-322 (2005) (Pubitemid 41368484)